Pular para o conteúdo

$IOVA $2 to $14 | Holy Grail of Cancer Therapy

6 de outubro de 2026 · 1 h 29 min

Notas do episódio

Avi Mash hosts Iovance ($IOVA) investor Minnesota Gopher and trader Father of Trades to discuss Iovance's IL-12 tethered TIL program, Amtagvi data in melanoma, non small cell lung cancer, endometrial cancer and sarcoma, FDA CNPV vouchers, a possible Merck buyout, and short selling in biotech. Father of Trades reviews the $IOVA chart and options chain and compares it to $SLS. Minnesota Gopher expects 18 to 22 by year end, and over 30 if a voucher basket is accepted.

This podcast is powered by Scanley, AI visibility for banks and credit unions. Get your 1st month free with code DAILYSTACK at https://meetscanley.com

Taking a BTC loan? Our friends at Ledn are offering .25% off their lowest rates with our link: https://www.ledn.io/partner/dailystack

Chapters:
0:00 Intro music
4:43 Minnesota Gopher on $IOVA and biotech short selling
15:37 IL-12 tethered TIL: holy grail of cancer therapy
22:19 Amtagvi frontline push and Keytruda style expansion
24:54 Biotech lagging the market and AI in medicine
29:06 FDA timelines, China drugs and CNPV vouchers
36:08 Iovance buyout, Merck and global distribution
44:04 Lung, melanoma, endometrial and sarcoma TIL data
56:23 $IOVA chart, volume profile and key levels
1:04:10 $IOVA options chain, open interest and gamma ramp
1:14:45 $IOVA price targets and the $SLS comparison
1:24:21 Father of Trades on BlackBerry QNX and holding winners

Key takeaways:
- Minnesota Gopher calls Iovance's IL-12 tethered TIL a potential holy grail because, in his view, it could turn cold tumors hot and make them treatable.
- Minnesota Gopher cited company figures: a 64.3% response rate in EGFR non small cell lung cancer with Keytruda and a 65.2% response rate in frontline melanoma with Keytruda.
- Minnesota Gopher believes Iovance's new FDA and regulatory hires point to a basket submission for CNPV vouchers in non small cell lung cancer, endometrial cancer and sarcoma, and he named Merck as the likeliest acquirer.
- Father of Trades read the options chain as pinning $IOVA near $14 in the short term and said a move above $20 could set up a gamma squeeze, as he saw in $SLS.
- Father of Trades said scalping profits should be parked in high conviction companies and gains should be protected by taking back cost basis on 10x or 15x winners.

Listen and follow The Daily Stack:
Spotify: https://open.spotify.com/show/0JQzqfVmkKiXuwSA6hyoDs
Apple Podcasts: https://podcasts.apple.com/us/podcast/the-daily-stack/id1831884653
Website: https://dailystackhq.com
X: https://x.com/dailystackHQ

Not financial advice.

Todos os episódios de The Daily Stack

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.